2024-12-22-PitchBook-PitchBook年三季度制药技术报告（英）_12页_10mb

Pharmatech Research Summary - Q3 2024

Core Content

This report provides an overview of the pharmatech sector, focusing on venture capital (VC) and private equity (PE) trends, innovation highlights, and key company developments in Q3 2024. It outlines the investment landscape, including deal activity, funding rounds, and market dynamics, while emphasizing the role of emerging technologies in advancing drug discovery and manufacturing processes.

Main Points

VC Funding Trends

• Total Funding: $1.1 billion across 65 deals in Q3 2024, a slight decrease from $1.2 billion across 47 deals in Q2.
• Deal Size: Focus on smaller deals with a larger number of transactions.
• Notable Deals:
  • Colossal Biosciences: $162.6 million Series B for genomics tools and services.
  • Cradle Bio: $73 million Series B for AI protein engineering.
  • CytoReason: $80 million Series B for AI disease modeling.
  • Viome Life Sciences: $25.4 million Series D for nucleic acids research.
  • OneSource Specialty Pharma: $199 million later-stage VC round to establish a CDMO.

PE Activity

• Buyout Deals: 56 in 2024, totaling $5.6 billion.
• Growth Equity Deals: 22 in 2024, valued at $1.9 billion.
• Notable Transactions:
  • MBK Partners: $2.2 billion LBO for Alinamin Pharmaceutical.
  • Cooper Consumer Health: $2.2 billion LBO for a Viatrix subsidiary.
  • BIOVECTRA: Acquired by Agilent Technologies for $925 million, enhancing manufacturing capabilities.

VC Exit Activity

• Exits: 7 in Q3 2024, up from 4 in Q2.
• PE Exit Activity: Shows positive signs with significant exits, indicating continued interest in the pharmatech sector.

Innovation Spotlights

Cell-Free Manufacturing

• A key innovation in drug discovery and biological research.
• Enables faster and more efficient protein production, supporting both research and development phases.

DNA Synthesis Services

• Highlighted as a growing area within the pharmatech sector.
• Facilitates the development of new biologics and small molecules through advanced synthesis technologies.

Key Company Highlights

Nuclera

• Overview: A biotech company focused on automated protein expression platforms.
• Technology: Integrates cell-free protein synthesis and digital microfluidics on smart cartridges.
• Leadership: Founded by Michael Chen (CEO), Jiahao Huang (CFO), and Gordon Herling-McInroy (COO).
• Recent Funding: Raised $75.4 million in Series C funding led by Elevage Medical Technologies.
• Total Raised: $154.5 million.
• First Institutional Round: $0.8 million seed round in 2014.
• Market Position: Aims to transform protein synthesis from a service into a lab-in-a-box solution.
• Competition: Faces startups like Tierra Biosciences and LenioBio.
• Exit Potential: Positioned for IPO or M&A, with a focus on global expansion and becoming a unicorn.

Market Map Insights

• VC Ecosystem: Includes 65 deals in Q3 2024, with a focus on CRO, CMO, and CDMO categories.
• PE Ecosystem: Reflects 56 buyout deals and 22 growth equity deals in 2024, indicating a strong interest in mature companies with revenue streams.
• Investor Interest: Strong presence of institutional investors and strategic partnerships, especially in the US and Europe.

Outlook and Trends

• PE Activity: Expected to remain strong due to favorable conditions post-US election, with a focus on manufacturing, SaaS, and specialized pharma.
• VC Activity: Slight decline in funding, but increased number of smaller deals suggests a shift towards broader market participation.
• Technological Advancements: Cell-free manufacturing and AI-driven tools are central to innovation in the pharmatech space.
• Strategic Shifts: PE investors are focusing on mature companies with established revenue, while VC investors are supporting early-stage startups with growth potential.

Conclusion

The pharmatech sector continues to evolve, with VC and PE activity reflecting a mix of strategic investments and market expansion. Innovations in protein synthesis and AI-driven solutions are driving growth, and companies like Nuclera are at the forefront, leveraging technology to streamline drug discovery and manufacturing. The sector remains attractive for investors, especially in the context of ongoing industry consolidation and the potential for both IPO and M&A exits.